Lipistad
Atorvastatin Statin for High Cholesterol and Cardiovascular Risk Reduction
Quick Facts About Lipistad
Key Takeaways About Lipistad
- Proven cardiovascular protection: Atorvastatin significantly reduces the risk of heart attack, stroke, and cardiovascular death, as demonstrated in large-scale clinical trials such as ASCOT-LLA and CARDS
- Once-daily convenience: Unlike some older statins, atorvastatin has a long duration of action and can be taken at any time of day, with or without food
- Watch for muscle symptoms: Report any unexplained muscle pain, tenderness, or weakness to your doctor immediately, as this could indicate a rare but serious condition called rhabdomyolysis
- Contraindicated in pregnancy: Lipistad must not be used during pregnancy, breastfeeding, or if you are a woman of childbearing potential not using reliable contraception
- Multiple drug interactions: Atorvastatin interacts with many medications including cyclosporine, certain antibiotics, antifungals, and HIV medications – always inform your doctor about all medicines you take
What Is Lipistad and What Is It Used For?
Lipistad contains atorvastatin, a medicine belonging to a group of drugs called statins (HMG-CoA reductase inhibitors) that regulate blood lipids (fats). It is prescribed to lower high cholesterol and triglycerides when diet and lifestyle changes are insufficient, and to reduce cardiovascular risk in patients with multiple risk factors.
Lipistad is used primarily for the treatment of hypercholesterolaemia (elevated blood cholesterol) and mixed dyslipidaemia (elevated cholesterol and triglycerides). Cholesterol is a waxy, fat-like substance found in the blood that is essential for building cell membranes and producing hormones. However, when levels of low-density lipoprotein (LDL) cholesterol – often called "bad cholesterol" – become too high, it accumulates in the walls of arteries, forming plaques. This process, known as atherosclerosis, narrows and hardens the arteries, increasing the risk of heart attack, stroke, and peripheral arterial disease.
Atorvastatin works by competitively inhibiting HMG-CoA reductase, the enzyme that catalyses the rate-limiting step in hepatic cholesterol synthesis. By reducing cholesterol production in the liver, it triggers an upregulation of LDL receptors on the surface of liver cells (hepatocytes), which then remove more LDL cholesterol from the bloodstream. The result is a significant reduction in total cholesterol, LDL cholesterol, apolipoprotein B, and triglycerides, along with a modest increase in HDL cholesterol ("good cholesterol").
Beyond its lipid-lowering effects, atorvastatin has been shown to have pleiotropic benefits that contribute to cardiovascular protection. These include stabilisation of atherosclerotic plaques, reduction of vascular inflammation, improvement of endothelial function, and antithrombotic effects. These properties help explain why statins reduce cardiovascular events even in patients whose baseline cholesterol levels are not markedly elevated.
If you have an increased risk of heart disease, Lipistad can be used to reduce that risk even if your cholesterol levels are within the normal range. The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), as well as the American College of Cardiology (ACC) and American Heart Association (AHA), recommend statins as first-line pharmacotherapy for primary and secondary cardiovascular prevention in patients at moderate to very high cardiovascular risk.
Atorvastatin was first approved for medical use in 1996 and is included on the World Health Organization's List of Essential Medicines, reflecting its importance in global healthcare. It is the most widely prescribed statin in the world, with hundreds of millions of prescriptions dispensed annually. Lipistad is manufactured by STADA Arzneimittel AG and is one of many generic atorvastatin formulations available worldwide, making effective cholesterol treatment widely accessible and affordable.
What Should You Know Before Taking Lipistad?
Before starting Lipistad, inform your doctor about all your medical conditions, especially liver disease, kidney problems, thyroid disorders, and any history of muscle problems. Lipistad is strictly contraindicated during pregnancy, breastfeeding, and in patients with active liver disease.
Contraindications
You should not take Lipistad if any of the following apply to you:
- Allergy to atorvastatin or any other ingredient in Lipistad (see the Contents section for a full list of ingredients)
- Active liver disease or unexplained persistent elevations in serum transaminases (liver enzymes) exceeding 3 times the upper limit of normal
- Pregnancy or trying to conceive – cholesterol and other products of cholesterol biosynthesis are essential for foetal development
- Breastfeeding – it is not known whether atorvastatin passes into breast milk, but statins are contraindicated during lactation
- Women of childbearing potential not using reliable contraception – effective birth control must be used throughout treatment
- Concurrent use of glecaprevir/pibrentasvir (a combination used to treat hepatitis C)
Warnings and Precautions
Talk to your doctor, pharmacist, or nurse before taking Lipistad if you have or have had any of the following conditions:
- Severe respiratory problems – additional monitoring may be necessary
- Current or recent use of fusidic acid (an antibiotic) – the combination with atorvastatin can cause serious muscle problems including rhabdomyolysis. If you need fusidic acid, your doctor will temporarily stop Lipistad
- Previous haemorrhagic stroke or small pockets of fluid in the brain from a previous stroke
- Kidney problems – renal impairment may increase the risk of muscle-related side effects
- Hypothyroidism (underactive thyroid) – untreated hypothyroidism increases the risk of statin-associated myopathy
- Unexplained or recurrent muscle pain, or a personal or family history of hereditary muscular disorders
- Previous muscle problems during treatment with other statins or fibrates
- Regular heavy alcohol consumption – increases the risk of liver damage
- Liver disease (current or history of) – liver function tests will be performed before and during treatment
- Age over 70 years – the risk of muscle-related side effects may be increased
- Myasthenia gravis or ocular myasthenia (diseases causing muscle weakness) – statins may occasionally worsen these conditions or trigger their onset
Your doctor will perform blood tests before starting treatment and periodically during treatment to monitor your liver function and assess the risk of muscle-related side effects. If you experience persistent, unexplained muscle weakness at any point during treatment, contact your doctor immediately, as additional tests and possible treatment adjustments may be necessary.
During treatment with Lipistad, your doctor will monitor you closely if you have diabetes or are at risk of developing diabetes. You are more likely to be at risk if you have high blood sugar and high blood fat levels, are overweight, or have high blood pressure. Statins have been associated with small increases in blood glucose levels and, in some patients, the onset of type 2 diabetes. However, the cardiovascular benefits of statin therapy generally far outweigh the small increase in diabetes risk.
Pregnancy and Breastfeeding
Lipistad must not be used during pregnancy, if you are trying to become pregnant, or if you are breastfeeding. Cholesterol and other products of cholesterol biosynthesis are essential components of foetal development, and inhibiting their synthesis could cause harm to the unborn child. Women of childbearing potential must use reliable contraception throughout treatment with Lipistad.
If you discover that you are pregnant while taking Lipistad, stop the medication immediately and contact your doctor. The safety of atorvastatin during pregnancy has not been established in humans. Your doctor will discuss alternative approaches to managing your cholesterol during pregnancy and breastfeeding.
Driving and Operating Machinery
Lipistad does not normally affect the ability to drive or use machines. However, if you notice that your ability is impaired – for example, due to dizziness, which is an uncommon side effect – you should not drive or operate machinery until the symptoms have resolved. Consult your doctor if you experience any effects that impact your ability to perform these activities safely.
Food, Drink, and Alcohol Interactions
Lipistad tablets can be taken at any time of day, with or without food. However, try to take your tablet at the same time each day for consistent drug levels. Unlike some older statins (such as simvastatin), atorvastatin does not need to be taken at bedtime because of its long duration of action.
Grapefruit juice: Do not drink more than one or two small glasses of grapefruit juice per day while taking Lipistad. Large quantities of grapefruit juice can inhibit the CYP3A4 enzyme responsible for metabolising atorvastatin, potentially leading to elevated drug levels and an increased risk of side effects, particularly muscle problems.
Alcohol: Avoid drinking excessive amounts of alcohol while taking Lipistad. Heavy alcohol consumption can increase the risk of liver problems. If you regularly consume alcohol, discuss this with your doctor before starting treatment.
Important Information About Some Ingredients
Lactose: Lipistad contains lactose monohydrate. If you have been told by your doctor that you have an intolerance to certain sugars, consult your doctor before taking this medicine.
Sodium: This medicine contains less than 1 mmol (23 mg) sodium per tablet, meaning it is essentially "sodium-free" and suitable for patients on a sodium-restricted diet.
How Does Lipistad Interact with Other Drugs?
Lipistad (atorvastatin) interacts with numerous medications, including immunosuppressants, certain antibiotics, antifungals, HIV medications, fibrates, and hepatitis C treatments. Some interactions significantly increase the risk of rhabdomyolysis (severe muscle breakdown). Always inform your doctor about all medicines you are taking.
Atorvastatin is primarily metabolised by the liver enzyme CYP3A4. Drugs that inhibit this enzyme can increase atorvastatin blood levels, while drugs that induce it can decrease its effectiveness. Additionally, some drugs can independently increase the risk of muscle damage when combined with statins. The following tables summarise the most clinically important interactions.
Major Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Cyclosporine | Immunosuppressant | Markedly increases atorvastatin levels; greatly increased risk of rhabdomyolysis | Avoid combination if possible; if unavoidable, do not exceed atorvastatin 10 mg/day |
| Glecaprevir/Pibrentasvir | Hepatitis C antivirals | Significantly increases atorvastatin exposure | Combination is contraindicated – do not use together |
| Fusidic acid (oral/injection) | Antibiotic | Increased risk of serious muscle problems including rhabdomyolysis | Temporarily stop Lipistad during fusidic acid treatment; resume 7 days after the last dose of fusidic acid |
| Gemfibrozil / other fibrates | Lipid-lowering agents | Independently increases risk of myopathy and rhabdomyolysis when combined with statins | Avoid combination with gemfibrozil; use other fibrates with caution and clinical monitoring |
| Tipranavir/Ritonavir | HIV protease inhibitors | Very potent CYP3A4 inhibition; greatly increases atorvastatin levels | Avoid combination; if needed, use lowest possible atorvastatin dose with close monitoring |
Moderate Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Erythromycin / Clarithromycin / Telithromycin | Macrolide antibiotics | CYP3A4 inhibitors that increase atorvastatin levels | Use with caution; consider temporary dose reduction of atorvastatin |
| Ketoconazole / Itraconazole / Voriconazole / Posaconazole | Azole antifungals | Potent CYP3A4 inhibitors; significantly increase atorvastatin levels | Limit atorvastatin dose; monitor for muscle symptoms |
| Ritonavir / Lopinavir / Atazanavir / Darunavir | HIV protease inhibitors | CYP3A4 inhibition increases atorvastatin exposure | Use lowest effective atorvastatin dose; monitor for side effects |
| Diltiazem / Verapamil / Amlodipine | Calcium channel blockers | Moderate CYP3A4 inhibition; may increase atorvastatin levels | Monitor for muscle symptoms; dose adjustment may be needed |
| Letermovir | Antiviral (CMV prevention) | Increases atorvastatin exposure | Do not exceed atorvastatin 20 mg/day during concurrent use |
| Warfarin | Anticoagulant | Atorvastatin may slightly affect warfarin metabolism | Monitor INR closely when starting, stopping, or changing atorvastatin dose |
| Elbasvir/Grazoprevir, Ledipasvir/Sofosbuvir | Hepatitis C antivirals | May increase atorvastatin levels | Limit atorvastatin dose; consult specialist guidance |
| Daptomycin | Antibiotic | Both drugs independently carry risk of myopathy; combined risk is additive | Consider temporary suspension of atorvastatin during daptomycin treatment |
| Colchicine | Gout treatment | Combined use may increase the risk of myopathy | Use with caution; monitor for muscle symptoms |
| St. John’s Wort (Hypericum perforatum) | Herbal supplement | CYP3A4 inducer that may reduce atorvastatin effectiveness | Avoid concurrent use |
| Rifampicin | Antibiotic (TB treatment) | Potent CYP3A4 inducer; significantly reduces atorvastatin levels | Monitor cholesterol levels; dose increase may be needed |
Other medicines that may interact with Lipistad include oral contraceptives (atorvastatin may increase oestrogen levels), digoxin (monitor digoxin levels), ezetimib (combined use is generally safe but monitor liver function), stiripentol (anti-epileptic), cimetidine, phenazone, and antacids containing aluminium or magnesium. Always tell your doctor or pharmacist about every medicine you are taking, including over-the-counter products and herbal supplements.
What Is the Correct Dosage of Lipistad?
The usual starting dose of Lipistad is 10 mg once daily for adults and children aged 10 years and older. Your doctor may gradually increase the dose up to a maximum of 80 mg once daily. Take the tablet at the same time each day, with or without food.
Always take Lipistad exactly as your doctor or pharmacist has told you. Do not change your dose without first consulting your doctor. Before starting treatment, your doctor will place you on a cholesterol-lowering diet, which you should continue to follow throughout the course of therapy.
Adults
High Cholesterol (Hypercholesterolaemia / Mixed Dyslipidaemia)
Starting dose: 10 mg once daily
Dose adjustments: Your doctor may increase the dose gradually at intervals of 4 weeks or more
Maximum dose: 80 mg once daily
The dose required depends on your individual cholesterol levels, treatment goals, and how well you respond to the medication. Most patients achieve adequate cholesterol control with 10–20 mg daily. Higher doses (40–80 mg) are reserved for patients who need more intensive lipid lowering, such as those with familial hypercholesterolaemia or very high cardiovascular risk.
Cardiovascular Risk Reduction
Dose: 10–80 mg once daily
For primary prevention of cardiovascular events in patients with elevated risk factors (such as diabetes, high blood pressure, smoking, or family history of early heart disease), the dose is determined based on your overall cardiovascular risk profile and current guidelines. For secondary prevention (after a heart attack or stroke), higher doses (typically 40–80 mg) are often recommended to achieve lower LDL targets.
Children and Adolescents (10 years and older)
Heterozygous Familial Hypercholesterolaemia
Starting dose: 10 mg once daily
Maximum dose: 80 mg once daily (adjusted at intervals of 4 weeks or more)
Atorvastatin is approved for children aged 10 years and older with heterozygous familial hypercholesterolaemia when diet therapy has not achieved adequate cholesterol reduction. Treatment should be supervised by a specialist experienced in paediatric lipid disorders.
Elderly Patients
No dose adjustment is required for elderly patients. The standard dosing recommendations apply. However, as the risk of muscle-related side effects may increase with age, elderly patients should be monitored carefully, especially at higher doses. Your doctor will take your overall health status, kidney function, and concurrent medications into account when determining the appropriate dose.
Missed Dose
If you forget to take a dose, simply skip the missed dose and take your next dose at the usual time the following day. Do not take a double dose to compensate for the missed one. If you frequently forget doses, consider setting a daily alarm or linking your tablet to a routine activity such as a meal.
Overdose
If you take more Lipistad than you should, or if a child accidentally swallows the medication, contact your doctor, hospital, or local poison control centre immediately for an assessment of the risk and advice. There is no specific antidote for atorvastatin overdose. Treatment is supportive and symptom-based. Because atorvastatin is highly bound to plasma proteins, haemodialysis is not expected to significantly remove the drug from the body.
Stopping Lipistad
Do not stop taking Lipistad without consulting your doctor, even if you feel well. High cholesterol typically causes no symptoms, so you may not notice any difference. However, stopping statin therapy can lead to a rise in cholesterol levels and an increase in cardiovascular risk. Your doctor will advise you on the duration of treatment, which in most cases is long-term.
What Are the Side Effects of Lipistad?
Common side effects of Lipistad include nasal inflammation, headache, muscle and joint pain, digestive disturbances, and abnormal liver function test results. Rare but serious side effects include rhabdomyolysis (severe muscle breakdown), severe allergic reactions, and hepatitis. Report any unexplained muscle pain or weakness to your doctor immediately.
Like all medicines, Lipistad can cause side effects, although not everybody gets them. Most side effects are mild and transient. However, some side effects require immediate medical attention.
- Severe allergic reaction causing swelling of the face, tongue, and throat that may cause great difficulty in breathing
- Serious skin peeling and swelling, blistering of the skin, mouth, eyes, and genitals, and fever – pink-red blotches, especially on palms or soles, that may blister (Stevens-Johnson syndrome)
- Muscle weakness, tenderness, pain, or muscle rupture, particularly if accompanied by feeling unwell or high fever – these may be signs of rhabdomyolysis, which can be life-threatening and lead to kidney damage
- Unexpected or unusual bleeding or bruising, which may indicate liver involvement
Common
May affect up to 1 in 10 people
- Nasal inflammation, sore throat, nosebleeds
- Allergic reactions
- Increased blood sugar levels (monitor closely if you have diabetes)
- Elevated blood creatine kinase levels
- Headache
- Nausea, constipation, flatulence, indigestion, diarrhoea
- Joint pain, muscle pain, back pain
- Blood test results showing abnormal liver function
Uncommon
May affect up to 1 in 100 people
- Loss of appetite (anorexia), weight gain, decreased blood sugar levels
- Nightmares, insomnia
- Dizziness, numbness or tingling in fingers and toes
- Reduced sensitivity to pain or touch, changes in taste perception
- Memory loss
- Blurred vision
- Tinnitus (ringing in the ears)
- Vomiting, belching, upper and lower abdominal pain
- Pancreatitis (inflammation of the pancreas)
- Hepatitis (liver inflammation)
- Rash, skin eruption, itching, hives, hair loss
- Neck pain, muscle fatigue
- Tiredness, feeling unwell, weakness, chest pain, swelling (oedema), raised temperature
- White blood cells in urine
Rare
May affect up to 1 in 1,000 people
- Visual disturbances
- Unexpected bleeding or bruising
- Cholestasis (jaundice – yellowing of the skin and eyes)
- Tendon injury
- Lichenoid drug eruption (skin rash in the mouth or on the skin)
- Purplish skin lesions (signs of blood vessel inflammation, vasculitis)
- Rhabdomyolysis (severe muscle breakdown) – muscle weakness, tenderness, pain, dark-coloured urine
- Severe allergic reaction with swelling and breathing difficulties (angioedema)
- Stevens-Johnson syndrome / toxic epidermal necrolysis (severe skin reactions)
Very Rare and Frequency Not Known
Very rare: up to 1 in 10,000 people; Not known: frequency cannot be estimated
- Hearing loss
- Gynaecomastia (breast enlargement in men)
- Lupus-like syndrome (including rash, joint disorders, effects on blood cells)
- Persistent muscle weakness (immune-mediated necrotising myopathy)
- Myasthenia gravis (generalised muscle weakness, including breathing muscles)
- Ocular myasthenia (muscle weakness affecting the eye)
- Sexual difficulties, depression
- Breathing problems including persistent cough and/or shortness of breath or fever
- Diabetes mellitus (more likely in patients with high blood sugar, overweight, and high blood pressure)
If you experience weakness in the arms or legs that worsens after periods of activity, double vision, drooping eyelids, difficulty swallowing, or breathlessness, contact your doctor. These may be symptoms of myasthenia gravis or ocular myasthenia.
If you experience any side effects not listed here, or if any side effect becomes severe, contact your doctor or pharmacist. Reporting suspected side effects helps ensure ongoing monitoring of the medicine's benefit-risk balance.
How Should You Store Lipistad?
Store Lipistad at room temperature with no special storage requirements. Keep it out of the sight and reach of children. Do not use the tablets after the expiry date printed on the packaging.
No special storage conditions are required for Lipistad film-coated tablets. Store the medicine in its original packaging to protect it from moisture. Check the expiry date (marked "EXP" on the blister and carton) before taking any tablets. The expiry date refers to the last day of the stated month.
Do not flush unused tablets down the toilet or throw them in household waste. Return any unused or expired medication to your pharmacy for safe disposal. This helps protect the environment from pharmaceutical contamination.
What Does Lipistad Contain?
Each Lipistad tablet contains atorvastatin (as atorvastatin calcium trihydrate) as the active ingredient, along with several inactive ingredients for tablet manufacture. Tablets are white to off-white, round, and biconvex, available in 10 mg, 20 mg, 40 mg, and 80 mg strengths.
Active Ingredient
The active substance is atorvastatin. Each film-coated tablet contains atorvastatin as atorvastatin calcium trihydrate in the following strengths:
- 10 mg tablet: contains 10 mg atorvastatin
- 20 mg tablet: contains 20 mg atorvastatin
- 40 mg tablet: contains 40 mg atorvastatin
- 80 mg tablet: contains 80 mg atorvastatin
Inactive Ingredients (Excipients)
The other ingredients are:
- Tablet core: Lactose monohydrate, cellulose powder, calcium carbonate, pregelatinised starch, hypromellose, croscarmellose sodium, magnesium stearate
- Film coating: Hypromellose, macrogol, titanium dioxide (E 171), talc
Tablet Appearance and Packaging
10 mg tablets: White to off-white, round, biconvex film-coated tablets; diameter approximately 6 mm.
20 mg tablets: White to off-white, round, biconvex film-coated tablets; diameter approximately 8 mm.
40 mg tablets: White to off-white, round, biconvex film-coated tablets; diameter approximately 10 mm.
80 mg tablets: White to off-white, round, biconvex film-coated tablets; diameter approximately 12 mm.
Available in OPA/Al/PVC-Al blister packs of 4, 7, 10, 14, 20, 28, 30, 50, 56, 84, 90, 98, 100, 112, 120, 180, and 500 film-coated tablets. Not all pack sizes may be marketed in your country.
Marketing Authorisation Holder and Manufacturer
Marketing authorisation holder: STADA Arzneimittel AG, Stadastrasse 2–18, 61118 Bad Vilbel, Germany.
This medicine is manufactured at multiple sites including facilities in Germany, Austria, the Netherlands, Ireland, Iceland, and Romania.
How Does Lipistad Work in the Body?
Lipistad works by inhibiting HMG-CoA reductase, the key enzyme in hepatic cholesterol synthesis. This causes the liver to increase its uptake of LDL cholesterol from the blood, resulting in a significant reduction in LDL cholesterol, total cholesterol, and triglycerides. The effect is dose-dependent, with reductions of 30–55% in LDL cholesterol achievable.
Cholesterol synthesis in the body follows a complex biochemical pathway known as the mevalonate pathway. The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase catalyses the conversion of HMG-CoA to mevalonate, which is the rate-limiting step in this pathway. Atorvastatin is a competitive inhibitor of this enzyme, meaning it competes with HMG-CoA for the enzyme's active site, thereby reducing the rate of cholesterol production.
When hepatic cholesterol synthesis is reduced, the liver compensates by increasing the expression of LDL receptors on the surface of hepatocytes. These receptors bind to LDL particles circulating in the blood and internalise them, effectively removing LDL cholesterol from the bloodstream. This mechanism accounts for the primary cholesterol-lowering effect of atorvastatin. In clinical studies, atorvastatin 10 mg reduces LDL cholesterol by approximately 37%, 20 mg by 43%, 40 mg by 50%, and 80 mg by 55%.
In addition to LDL reduction, atorvastatin lowers triglycerides by 14–33% and raises HDL cholesterol by 5–10%. It also reduces levels of apolipoprotein B (the protein component of LDL particles) and very-low-density lipoprotein (VLDL) cholesterol.
Pleiotropic Effects
Beyond lipid lowering, atorvastatin exerts several additional cardiovascular protective effects that are collectively known as pleiotropic effects:
- Plaque stabilisation: Statins reduce the lipid content and inflammatory cell infiltration of atherosclerotic plaques, making them less likely to rupture and cause an acute coronary event
- Anti-inflammatory effects: Atorvastatin reduces circulating levels of C-reactive protein (CRP) and other inflammatory markers, reflecting a reduction in vascular inflammation
- Endothelial function improvement: Statins increase nitric oxide bioavailability, improving blood vessel dilation and function
- Antithrombotic effects: Atorvastatin reduces platelet aggregation and thrombin generation, lowering the risk of blood clot formation
Pharmacokinetic Profile
After oral administration, atorvastatin is rapidly absorbed from the gastrointestinal tract. Absolute bioavailability is approximately 12%, which reflects extensive first-pass metabolism in the gut wall and liver. Despite the low systemic bioavailability, the drug reaches its primary site of action (the liver) effectively. Peak plasma concentrations are reached within 1–2 hours of oral dosing.
Atorvastatin is highly protein-bound (approximately 98%) and is metabolised primarily by CYP3A4 in the liver. It has two active metabolites (ortho- and para-hydroxylated derivatives) that contribute to approximately 70% of the circulating HMG-CoA reductase inhibitory activity. The plasma elimination half-life of atorvastatin is approximately 14 hours, but the effective half-life of HMG-CoA reductase inhibition is 20–30 hours due to the contribution of its active metabolites. This long duration of action is why atorvastatin can be taken at any time of day, unlike some other statins.
Less than 2% of an oral dose is recovered in the urine. Atorvastatin is eliminated primarily via biliary excretion. No dose adjustment is needed for patients with kidney impairment, as renal disease does not significantly affect atorvastatin pharmacokinetics.
Frequently Asked Questions About Lipistad
Lipistad contains atorvastatin, a statin used to lower high cholesterol and triglycerides in the blood when diet and lifestyle changes alone are not sufficient. It is also prescribed to reduce the risk of cardiovascular events (such as heart attack and stroke) in patients with risk factors, even if their cholesterol levels are within the normal range. It works by inhibiting cholesterol production in the liver and increasing the liver's ability to clear LDL cholesterol from the blood.
The most common side effects include nasal inflammation, sore throat, nosebleeds, allergic reactions, increased blood sugar, headache, nausea, constipation, flatulence, indigestion, diarrhoea, joint pain, muscle pain, back pain, and abnormal liver function tests. Most of these side effects are mild and tend to improve over time. However, if you experience unexplained muscle pain, tenderness, or weakness, contact your doctor immediately as this may indicate a rare but serious condition.
No. Lipistad must not be used during pregnancy, if you are trying to conceive, or if you are breastfeeding. Cholesterol and its biosynthetic intermediates are essential for foetal development, and blocking their production could harm the developing baby. Women of childbearing potential must use reliable contraception throughout treatment. If you become pregnant while taking Lipistad, stop the medication immediately and contact your doctor.
Lipistad can be taken at any time of day, with or without food. Unlike some older statins (such as simvastatin or lovastatin) that should ideally be taken in the evening, atorvastatin has a long duration of action that provides 24-hour cholesterol-lowering activity regardless of when it is taken. The most important thing is to take it at the same time each day for consistency.
You should limit your intake to no more than one or two small glasses of grapefruit juice per day. Grapefruit juice contains compounds called furanocoumarins that inhibit the CYP3A4 enzyme in the gut and liver, which is responsible for breaking down atorvastatin. Large quantities can lead to increased atorvastatin levels in the blood, raising the risk of side effects, particularly muscle problems.
Contact your doctor as soon as possible if you experience unexplained muscle pain, tenderness, weakness, or cramps. While muscle-related side effects are usually mild and reversible, in rare cases statins can cause a serious condition called rhabdomyolysis, which involves the breakdown of muscle tissue and can lead to kidney damage. Your doctor may test your creatine kinase (CK) blood levels and decide whether to reduce your dose, switch to a different statin, or temporarily stop treatment.
References
This article is based on the following international medical guidelines and peer-reviewed sources. All medical claims have evidence level 1A, the highest quality of evidence based on systematic reviews of randomised controlled trials.
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111–188. doi:10.1093/eurheartj/ehz455
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019;73(24):e285–e350.
- National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guideline [CG181]. Updated 2023.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list. Geneva: WHO; 2023.
- European Medicines Agency (EMA). Atorvastatin – Summary of Product Characteristics. EMA product information database. Accessed January 2026.
- Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. The Lancet. 2010;376(9753):1670–1681.
- Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA). The Lancet. 2003;361(9364):1149–1158.
- Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). The Lancet. 2004;364(9435):685–696.
- British National Formulary (BNF). Atorvastatin. NICE BNF monograph. Accessed January 2026.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians with expertise in cardiology, clinical pharmacology, and internal medicine.
Medical Writers
Board-certified physicians specialising in cardiovascular medicine and clinical pharmacology with documented academic and clinical experience.
Medical Reviewers
Independent review board ensuring clinical accuracy, adherence to international guidelines (ESC, EAS, AHA, NICE, WHO), and evidence level 1A standards.
All content follows the GRADE evidence framework and is reviewed against current international guidelines. We have no commercial funding or pharmaceutical sponsorship. For more information, see our editorial standards and medical team pages.